5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder

Neuropsychopharmacology

Volumn 41, Issue 4, 2016, Pages 1093-1102

  Martinez, Pedro E ^a   Rubinow, David R ^b   Nieman, Lynnette K ^c   Koziol, Deloris E ^d   Morrow, A Leslie ^b   Schiller, Crystal E ^b   Cintron, Dahima ^e   Thompson, Karla D ^a   Khine, Khursheed K ^a   Schmidt, Peter J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; DUTASTERIDE; PROGESTERONE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; ANDROSTERONE; CHOLESTENONE 5ALPHA REDUCTASE; ELTANOLONE; PREGNENOLONE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ANXIETY; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; GESTAGEN BLOOD LEVEL; HUMAN; IRRITABILITY; LOW DRUG DOSE; LUTEAL PHASE; MENSTRUAL CYCLE; PARITY; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGESTERONE RELEASE; RANDOMIZED CONTROLLED TRIAL; SADNESS; SINGLE BLIND PROCEDURE; SYMPTOM; BLOOD; ENZYMOLOGY; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

5-ALPHA REDUCTASE INHIBITORS; ADULT; ANDROSTERONE; CHOLESTENONE 5 ALPHA-REDUCTASE; DOUBLE-BLIND METHOD; DUTASTERIDE; FEMALE; HUMANS; LUTEAL PHASE; MIDDLE AGED; PREGNANOLONE; PREGNENOLONE; PREMENSTRUAL DYSPHORIC DISORDER; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 84957846559     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.246     Document Type: Article

References (47)

1. Agis-Balboa RC, Guidotti A, Pinna G (2014). 5α-reductase type I expression is downregulated in the prefrontal cortex/Brodmann's area 9 (BA9) of depressed patients. Psychopharmacology 231: 3569-3580.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, American Psychiatric Association: Washington, DC, USA.
3. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association: Arlington, VA, USA.
4. Backström T, Haage D, Löfgren M, Johansson IM, Strömberg J, Nyberg S et al (2011). Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience 191: 46-54.
5. Bixo M, Andersson A, Winblad B, Purdy RH, Backström T (1997). Progesterone, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 764: 173-178.
6. Bortolato M, Frau R, Orru M, Bourov Y, Marrosu F, Mereu G et al (2008). Antipsychotic-like properties of 5-α-reductase inhibitors. Neuropsychopharmacology 33: 3146-3156.
7. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV (1997). Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 282: 1496-1502.
8. Devoto P, Frau R, Bini V, Pillolla G, Saba P, Flore G et al (2012). Inhibition of 5α-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation. Psychoneuroendocrinology 37: 1630-1645.
9. Endicott J, Nee J, Cohen J, Halbreich U (1986). Premenstrual changes: patterns and correlates of daily ratings. J Affect Disord 10: 127-135.
10. Epperson CN, Haga K, Mason GF, Sellers E, Gueorguieva R, Zhang W et al (2002). Cortical γ-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 59: 851-858.
11. First MB, Spitzer RL, Gibbon M, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). Biometric Research, New York State, Psychiatric Institute: New York.
12. Glaxo Smith Kline Research Triangle Park NC (2014). Avodart prescribing information. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing-Information/Avodart/pdf/AVODART-PI-PIL.PDF.
13. Glaxo Smith Kline Research Triangle Park NC (2005). GI198745: Quantitative whole-body autoradiography following single and repeated administration to the mouse.
14. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R (2006). Variants in the 5α-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab 91: 4085-4091.
15. Griffin LD, Mellon SH (1999). Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96: 13512-13517.
16. Gulinello M, Gong QH, Li X, Smith SS (2001). Short-term exposure to a neuroactive steroid increases α4 GABAA receptor subunit levels in association with increased anxiety in the female rat. Brain Res 910: 55-66.
17. Gulinello M, Smith SS (2003). Anxiogenic effects of neurosteroid exposure: sex differences and altered GABAA receptor pharmacology in adult rats. J Pharmacol Exp Ther 305: 541-548.
18. Hilsenroth MJ, Ackerman SJ, Blagys MD, Baumann BD, Baity MR, Smith SR et al (2000). Reliability and validity of DSM-IV axis V. Am J Psychiatry 157: 1858-1863.
19. Klatzkin RR, Morrow AL, Light KC, Pedersen CA, Girdler SS (2006). Histories of depression, allopregnanolone responses to stress, and premenstrual symptoms in women. Biol Psychol 71: 2-11.
20. Lombardi I, Luisi S, Quirici B, Monteleone P, Bernardi F, Liut M et al (2004). Adrenal response to adrenocorticotropic hormone stimulation in patients with premenstrual syndrome. Gynecol Endocrinol 18: 79-87.
21. Maguire JL, Stell BM, Rafizadeh M, Mody I (2005). Ovarian cyclelinked changes in GABAA receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 8: 797-804.
22. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986). Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232: 1004-1007.
23. Miller WL, Auchus RJ (2011). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32: 81-151.
24. Monteleone P, Luisi S, Tonetti A, Bernardi F, Genazzani AD, Luisi M et al (2000). Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 142: 269-273.
25. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML et al (2006). The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 55: 1014-1023.
26. Paba S, Frau R, Godar SC, Devoto P, Marrosu F, Bortolato M (2011). Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Curr Pharm Des 17: 151-167.
27. Paul SM, Purdy RH (1992). Neuroactive steroids. FASEB J 6: 2311-2322.
28. Pelletier G (2010). Steroidogenic enzymes in the brain: morphological aspects. Prog Brain Res 181: 193-207.
29. Porcu P, O'Buckley TK, Alward SE, Marx CE, Shampine LJ, Girdler SS et al (2009). Simultaneous quantification of GABAergic 3α,5α/3α,5β neuroactive steroids in human and rat serum. Steroids 74: 463-473.
30. Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB (1997). Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90: 709-714.
31. Rubinow DR, Roy-Byrne PP, Hoban MC, Gold PW, Post RM (1984). Prospective assessment of menstrually related mood disorders. Am J Psychiatry 141: 684-686.
32. Rubinow DR, Schmidt PJ (2006). Gonadal steroid regulation of mood: the lessons of premenstrual syndrome. Front Neuroendocrinol 27: 210-216.
33. Schiller CE, Schmidt PJ, Rubinow DR (2014). Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology 231: 3557-3567.
34. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 338: 209-216.
35. Schmidt PJ, Purdy RH, Moore PH Jr., Paul SM, Rubinow DR (1994). Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 79: 1256-1260.
36. Shen H, Gong QH, Aoki C, Yuan M, Ruderman Y, Dattilo M et al (2007). Reversal of neurosteroid effects at α4β2δ GABAA receptors triggers anxiety at puberty. Nat Neurosci 10: 469-477.
37. Shen H, Gong QH, Yuan M, Smith SS (2005). Short-term steroid treatment increases delta GABAA receptor subunit expression in rat CA1 hippocampus: pharmacological and behavioral effects. Neuropharmacology 49: 573-586.
38. Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM (2003). Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol Psychiatry 54: 757-762.
39. Sripada RK, Marx CE, King AP, Rampton JC, Ho SS, Liberzon I (2013). Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biol Psychiatry 73: 1045-1053.
40. Steckelbroeck S, Watzka M, Reichelt R, Hans VHJ, Stoffel-Wagner B, Heidrich DD et al (2001). Characterization of the 5α-reductase-3α-hydroxysteroid dehydrogenase complex in the human brain. J Clin Endocrinol Metab 86: 1324-1331.
41. Stoffel-Wagner B (2001). Neurosteroid metabolism in the human brain. Eur J Endocrinol 145: 669-679.
42. Stoffel-Wagner B, Beyenburg S, Watzka M, Blümcke I, Bauer J, Schramm J et al (2000). Expression of 5α-reductase and 3α-hydroxisteroid oxidoreductase in the hippocampus of patients with chronic temporal lobe epilepsy. Epilepsia 41: 140-147.
43. Sundstrom I, Andersson A, Nyberg S, Ashbrook D, Purdy RH, Backstrom T (1998). Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 67: 126-138.
44. Sundstrom I, Ashbrook D, Backstrom T (1997a). Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22: 25-38.
45. Sundstrom I, Nyberg S, Backstrom T (1997b). Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 17: 370-381.
46. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E et al (1998). Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95: 3239-3244.
47. Wang M, Seippel L, Purdy RH, Bäckström T (1996). Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J Clin Endocrinol Metab 81: 1076-1082.